On Monday, Shares of Ford Motor Co. (NYSE:F), gained 1.28% to $14.99.
Ford Motor Company is donating seven Ford Flex utility vehicles to the DAV, extending a strong relationship that has assisted disabled military veterans for 93 years.
The vehicles will become part of the DAV Transportation Network that enlists volunteer drivers to take sick and disabled veterans to VA medical centers across the country. They will be deployed to DAV locations in Little Rock, Arkansas, Iowa City, Iowa, Iron Mountain, Michigan, Omaha, Nebraska, Portland, Oregon, Salt Lake City, Utah and Seattle, Washington. Since 1996, Ford has donated 199 vehicles to the DAV fleet.
In addition to the new Ford Flex vehicles, Ford Fund, the philanthropic arm of Ford Motor Company, is sponsoring DAV 5K walks this fall in Atlanta, Cincinnati and San Diego. Ford Fund also is ongoing support for the Jesse Brown Memorial Youth Scholarship Program, which provides scholarships to deserving young men and women who have generously volunteered their time to assist disabled veterans in their community.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of RCS Capital Corporation (NYSE:RCAP), declined -35% to $2.60, during its last trading session, hitting its lowest level.
RCS Capital Corporation declared a series of planned transactions and initiatives designed to enhance shareholder value. In addition, RCS Capital declared its operating results for the three months ended June 30, 2015.
Planned Transactions and Initiatives
Consistent with the Board of Directors’ and administration’s formerly stated commitment to enhance shareholder value, the Company has reached a contract with an associate of Apollo Global Administration, LLC (APO) (together with its merged auxiliaries, “Apollo”), a leading global alternative investment manager, to sell RCS Capital’s Wholesale Distribution division and certain related entities, for $25 million in cash. The Company anticipates to utilize the net cash proceeds from the sale to reduce its outstanding senior secured indebtedness.
Further, Cetera Financial Group will also enter into a planned relationship with Apollo to offer alternative Apollo-sponsored investment products through Cetera’s open architecture network of independent financial advisors. Apollo presently manages more than $160 billion of assets across a broad spectrum of asset classes, geographies and strategies, many of which we expect will be attractive to retail investors seeking current income and increasing allocations to alternatives within their portfolios.
In addition, the Company declared that Apollo and associates of Luxor Capital Group (“Luxor”) have agreed to invest $37.5 million ($25 million from Apollo and $12.5 million from Luxor) in the Company through newly issued preferred stock. The Company intends to use the proceeds from this planned investment to provide additional liquidity and working capital to allow the Company to continue to capitalize on the attractive market environment.
RCS Capital Corporation engages in the independent retail advice, wholesale distribution, investment banking, capital markets, investment administration, and investment research businesses.
Finally, Novavax, Inc. (NASDAQ:NVAX), ended its last trade with 3.32% gain, and closed at $11.19.
Novavax declared its financial results for the second quarter and six months ended June 30, 2015.
Novavax Second Quarter and Subsequent Achievements:
- Declared positive top-line data from a Phase 2 trial of its RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The trial demonstrated statistically noteworthyvaccine efficacy in the prevention of symptomatic RSV disease in older adults, the first vaccine to demonstrate efficacy against RSV disease in any population. The trial detected an attack rate of 4.9% for symptomatic RSV disease in 1,600 older adults. Similar to the Company’s findings in preceding trials, there were greater than four-fold enhances in both anti-F IgG and palivizumab-competing antibody (PCA) concentrations with serological responses in over 90% of vaccinated participants.
- Declared positive top-line data from a Phase 2 trial of its recombinant quadrivalent seasonal influenza virus-like particle candidate (Quadrivalent Seasonal Influenza VLP). The trial, funded in whole or part with Federal funds from the Company’s contract with HHS BARDA, demonstrated that the Quadrivalent Seasonal Influenza VLP vaccine candidate was well-tolerated with no vaccine-related serious adverse events. The trial met its immunogenicity targets and demonstrated potential to meet the Center for Biological Evaluation and Research (CBER) criteria for accelerated approval.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
